Abstract: Objective To observe the effects of Bifidobacterium triple viable combined with thiabendazole treatment on clinical symptoms, immune function and intestinal flora of children with tic disorders. 
 Methods In total, 104 children with tic disorders admitted to the Department of Paediatrics of Cangzhou People′s Hospital in Hebei Province from March 2021 to March 2023 were selected and divided into the control group and the observation group using the random number table method. The control group was given thiabendazole hydrochloride, and the observation group was given Bifidobacterium triple viable combined with thiabendazole. The Yale Global Tic Severity Scale (YGTSS) score, American Spinal Injury Association (ASIA) score, immune function, and α diversity of intestinal flora before and after treatment were compared between the two groups. The incidence of adverse reactions in the two groups was calculated. 
 Results Before treatment, the differences in each index between the two groups were not statistically significant (P＞0.05). At 12 weeks after treatment, the total scores of motor tics, vocal tics, social function deficits, and YGTSS of the two groups were lower than those before treatment, while the motor and sensory scores of the ASIA score, CD3+, CD3+CD4+, CD4+/CD8+, Shannon index, Chao1 index, Sobs index, and Ace index were higher than those before treatment. The total scores of motor tics, vocal tics, social function deficits, and YGTSS of the observation group were lower than those of the control group, while the motor and sensory scores of the ASIA score, CD3+, CD3+CD4+, CD4+/CD8+, Shannon index, Chao1 index, Sobs index, and Ace index were higher than those of the control group, showing significant differences (P＜0.05). The total effective rate of the observation group ［94.23% (49/52)］ was higher than that of the control group ［80.77% (42/52)］, suggesting no significant difference (P＜0.05). The incidence rates of adverse reactions, such as dizziness, gastrointestinal discomfort, loss of appetite, and drowsiness, between the two groups ［13.46% (7/52) vs. 3.85% (3/52)］ showed no significant difference (P＞0.05). 
 Conclusion Bifidobacterium triple viable combined with thiabendazole in the treatment of children with tic disorders regulates immune function, improves the α diversity of the intestinal flora, and repairs damaged neurological function. 

Key words: tic disorders, Bifidobacterium triple viable, thiabendazole ,  ,